Tolnaftate

Summary

Tolnaftate (CHEMBL83668) is an approved small-molecule antifungal drug (ATC D01AE18); indicated across 5 conditions including tinea infection and tinea pedis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AE18
• Indications: 5 conditions
• Clinical trials: 1
• Chemistry: 307.4 Da · C19H17NOS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL83668
Name	Tolnaftate
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5510
ChEBI	CHEBI:9620
ATC	D01AE18
Molecular formula	C19H17NOS
Molecular weight	307.4
InChIKey	FUSNMLFNXJSCDI-UHFFFAOYSA-N

SMILES: CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2

IUPAC name: O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate

ChEBI definition: A monothiocarbamic ester that is the methyl(3-tolyl)carbamothioate ester of 2-naphthol. A synthetic anti-fungal agent used to treat jock itch, athlete’s foot and ringworm.

Pharmacological roles (ChEBI): antifungal drug.

Also known as: Mycil, NSC-233648, SCH 10144, SCH-10144, Separin, Timoped, Tinaderm, Tinaderm plus, Tineafax, Tolnaftate, Tolnaftato, SID11112516

Patent coverage: 5,955 distinct patent families (19,005 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 18,972 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Prelamin-A/C, Ferritin light chain, 5-hydroxytryptamine receptor 2B, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 3A4, Nuclear receptor subfamily 1 group I member 2, Cytochrome P450 2C19, Voltage-dependent L-type calcium channel subunit alpha-1C, Lanosterol 14-alpha demethylase, Mitogen-activated protein kinase 1, Lethal factor.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 26 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	7	Potency	100	nM	CHEMBL_ACT_4019463
CYP2C19	7	AC50	100	nM	CHEMBL_ACT_6069354
NR1I2	5.94	AC50	1150	nM	CHEMBL_ACT_25188228
CYP2C9	5.9	Potency	1259	nM	CHEMBL_ACT_5025349
CYP2C9	5.9	AC50	1259	nM	CHEMBL_ACT_6066882
HTR2B	5.89	Ki	1277	nM	CHEMBL_ACT_7819413
NR1I2	5.72	AC50	1917	nM	CHEMBL_ACT_25224376
HTR2B	5.7	IC50	2007	nM	CHEMBL_ACT_7819412
CYP1A2	5.6	AC50	2512	nM	CHEMBL_ACT_6007745
CYP2C19	5.52	IC50	3000	nM	CHEMBL_ACT_7817252
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_4973832
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_5042858
CYP3A4	5.4	AC50	3981	nM	CHEMBL_ACT_6066232
P15917	5.3	Potency	5012	nM	CHEMBL_ACT_4634310

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
tinea infection	4	MONDO:0005982	EFO:0007510
tinea pedis	4	MONDO:0005984	EFO:0007512

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01429701	PHASE3	COMPLETED	Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).